Oxagen Ltd
http://www.oxagen.co.uk/index.htm
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Oxagen Ltd
Novartis’s Fevipiprant Hit By Phase III Asthma Failure
Novartis’s investigational oral therapy for asthma fell at the first Phase III hurdle but pivotal studies in severe disease will be key to prospects.
Medical Device Deals Update, March 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced January-February 2016.
Redx appoints new CSO and CFO
UK-based Redx Pharma has promoted Dr Richard Armer to chief scientific officer and Phil Tottey to chief financial officer.
Teijin turns to Pulmagen to plug respiratory pipeline gap
The pharmaceutical division of Teijin has acquired rights in Japan to Pulmagen Therapeutics' lead CRTh2 antagonist ADC3680, which it will develop initially for bronchial asthma.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice